We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prognostic significance of nadir PSA value and time to nadir PSA in patients with metastatic castration-naive prostate cancer receiving first-line hormonotherapy.
- Authors
İnci, Bediz Kurt; Gürler, Fatih; Sütcüoğlu, Osman; Baştuğ, Vural; Yazıcı, Ozan; Üner, Aytuğ; Özet, Ahmet; Özdemir, Nuriye
- Abstract
Background: The current study aimed to evaluate the effect of the time duration to reach the lowest prostate-specific antigen (PSA) from the onset of first-line hormonal treatment (time to nadir PSA, TTNpsa) on survival in castration-naive metastatic prostate cancer (CN-MPC) patients. Methods: Eighty patients who had PSA response >80% with first-line hormonal therapy (luteinizing hormone-releasing hormone, LH-RH analog +/- bicalutamide) were included in this study. Results: Under androgen deprivation therapy (ADT), a significant positive correlation was found between TTNpsa, nadir PSA (Npsa) duration, and progression-free survival (PFS) (p < 0.001) and overall survival (OS) (p < 0.001). There was no correlation between TTNpsa and Npsa duration. TTNpsa and Npsa durations were independently correlated with PFS and OS. In patients with TTNpsa value =19 weeks, the median PFS was 126 (95% CI, 68-184) weeks compared with TTNpsa <19-week group in which the median PFS was 44 (95% CI, 26-62) weeks (p = 0.033). In patients with TTNpsa value =19 weeks, the median OS was 242 (95% CI, 169-315) weeks compared with TTNpsa <19-week group in which the OS was 156 (95% CI, 89-223) weeks (p = 0.018). The median nadir PSA value was 1 ng/mL. The median PFS was significantly longer in the patient group with =1 ng/mL (137 weeks, 95% CI, 50-224) compared with the group with >1 ng/mL (41 weeks, 95% CI, 34-48) (p < 0.001). The median OS was significantly longer in the patient group with nadir PSA =1 ng/mL (296 weeks, 95% CI, 220-272) compared to the group with >1 ng/mL (131 weeks, 95% CI, 84-178) (p = 0.002). In patients with nadir PSA =1 ng/mL (n = 40), there was no relationship between TTNpsa and Npsa duration with both PFS and OS. However, in patients with nadir PSA >1 ng/mL (n = 40) subgroup, there was a significant positive correlation between TTNpsa and PFS, and OS (p < 0.001, P = 0.016, respectively). Conclusion: In CN-MPC who received first-line ADT, especially in the group with the nadir PSA value >1 ng/mL, the duration of TTNpsa was positively correlated with PFS and OS.
- Subjects
PROSTATE-specific antigen; PROSTATE cancer; ANDROGEN deprivation therapy; OVERALL survival; PROGRESSION-free survival
- Publication
Journal of Cancer Research & Therapeutics, 2023, Vol 19, pS845
- ISSN
0973-1482
- Publication type
Article
- DOI
10.4103/jcrt.JCRT_1527_20